Acceleron Pharma Inc (NASDAQ:XLRN) SVP Christopher Rovaldi sold 11,000 shares of Acceleron Pharma stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $45.00, for a total value of $495,000.00. Following the completion of the transaction, the senior vice president now owns 35,701 shares of the company’s stock, valued at $1,606,545. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Christopher Rovaldi also recently made the following trade(s):

  • On Wednesday, January 3rd, Christopher Rovaldi sold 2,266 shares of Acceleron Pharma stock. The stock was sold at an average price of $42.42, for a total value of $96,123.72.

Shares of Acceleron Pharma Inc (NASDAQ XLRN) opened at $43.04 on Friday. The firm has a market capitalization of $2,035.12, a P/E ratio of -16.62 and a beta of 1.59. Acceleron Pharma Inc has a twelve month low of $23.07 and a twelve month high of $46.93.

Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.02. The company had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.55) earnings per share. sell-side analysts predict that Acceleron Pharma Inc will post -2.65 earnings per share for the current fiscal year.

A number of equities analysts recently commented on XLRN shares. Credit Suisse Group set a $51.00 price target on Acceleron Pharma and gave the stock a “buy” rating in a research note on Tuesday, November 14th. HC Wainwright started coverage on Acceleron Pharma in a research note on Thursday, October 12th. They issued a “buy” rating and a $57.00 price target for the company. Royal Bank of Canada reiterated a “hold” rating on shares of Acceleron Pharma in a research note on Thursday, November 2nd. Oppenheimer reiterated a “hold” rating on shares of Acceleron Pharma in a research note on Tuesday, November 14th. Finally, ValuEngine downgraded Acceleron Pharma from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $44.81.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of Acceleron Pharma by 9.0% during the second quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock valued at $121,719,000 after buying an additional 330,635 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Acceleron Pharma by 6.1% during the second quarter. Vanguard Group Inc. now owns 2,029,040 shares of the biopharmaceutical company’s stock valued at $61,663,000 after buying an additional 116,705 shares during the last quarter. Perceptive Advisors LLC raised its holdings in shares of Acceleron Pharma by 127.2% during the third quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock valued at $60,319,000 after buying an additional 905,000 shares during the last quarter. State Street Corp raised its holdings in shares of Acceleron Pharma by 9.4% during the second quarter. State Street Corp now owns 1,131,824 shares of the biopharmaceutical company’s stock valued at $34,386,000 after buying an additional 97,199 shares during the last quarter. Finally, Sectoral Asset Management Inc raised its holdings in shares of Acceleron Pharma by 378.2% during the second quarter. Sectoral Asset Management Inc now owns 604,499 shares of the biopharmaceutical company’s stock valued at $18,371,000 after buying an additional 478,099 shares during the last quarter. 85.70% of the stock is currently owned by institutional investors.

WARNING: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2018/01/20/insider-selling-acceleron-pharma-inc-xlrn-svp-sells-11000-shares-of-stock.html.

About Acceleron Pharma

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.